bullish

Dong A St

Dong-A ST (170900 KS/Buy)Top-Line Growth Continues, but Margin Improvement Remains Limited

117 Views12 Feb 2026 08:07
Broker
Imuldosa (Stelara biosimilar), previously treated as a pipeline asset and valued at W111.1bn, has now been incorporated into operating value following commercialization.
What is covered in the Full Insight:
  • Introduction
  • Financial Overview
  • 2025 Review and 2026 Outlook
  • Pipeline Update
  • Valuation Metrics
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 15-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Dong-A ST (170900 KS/Buy)Top-Line Growth Continues, but Margin Improvement Remains Limited
    12 Feb 2026
x